SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technolog...
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technolog...
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technolog...
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technolog...
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technolog...
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technolog...
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technolog...
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technolog...
Rigosertib sodium is under clinical development by Traws Pharma and currently in...
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technolog...
ABBV-400 is a monoclonal antibody conjugated commercialized by AbbVie, with a le...
Sabestomig is a monoclonal antibody commercialized by AstraZeneca, with a leadin...
AZD-9574 is a small molecule commercialized by AstraZeneca, with a leading Phase...
MK-1084 is a small molecule commercialized by Merck, with a leading Phase I prog...
XXB-750 is a monoclonal antibody commercialized by Novartis, with a leading Phas...
NNC0519-0130 is commercialized by Novo Nordisk, with a leading Phase II program...
